Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Melanoma 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 33Docetaxel 10Nivolumab 9Paclitaxel 6Trastuzumab 5Gemcitabine 5Cetuximab 5Carboplatin 5Capecitabine 5Fulvestrant 4Cyclophosphamide 4spartalizumab 3poly ICLC 3durvalumab 3avelumab 3Oxaliplatin 3Leucovorin 3Ipilimumab 3Fluorouracil 3Cisplatin 3Biopsy 3zimberelimab 2tremelimumab 2palbociclib 2obinutuzumab 2lenvatinib 2cemiplimab 2budigalimab 2Vorinostat 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × C188-9 compound × Breast × Clear all
NCT03195699 2025-03-21

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Tvardi Therapeutics, Incorporated

Phase 1 Completed
64 enrolled
BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡